DFV Coliplus

Main information

  • Trade name:
  • DFV Coliplus
  • Pharmaceutical form:
  • Oral solution
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • DFV Coliplus
    Netherlands
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • colistin
  • Therapeutic area:
  • Cattle Young, Chicken, Other Young, Pigs

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • UK/V/0313/001
  • Authorization date:
  • 28-10-2010
  • EU code:
  • UK/V/0313/001
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

Revised:December2010

AN:00921/2010

Page1of6

SUMMARYOFPRODUCTCHARACTERISTICS

1. NAMEOFTHEVETERINARYMEDICINALPRODUCT

Coliplus2,000,000IU/mlConcentrateforOralSolutionforuseindrinking

waterforCattle,Sheep,SwineandChickens

ES:ColistinaDivasa2,000,000IU/mlConcentrateforOralSolutionforusein

drinkingwaterforCattle,Sheep,SwineandChickens

2. QUALITATIVEANDQUANTITATIVECOMPOSITION

Compositionfor1ml:

Activesubstance:

Colistin(asColistinsulfate) 2MIU(equivalentto83.33mg)

Excipient(s):

BenzylAlcohol 10mg

Disodiumedetate 0.1mg

Excipientsqs 1ml

Forafulllistofexcipients,seesection6.1.

3. PHARMACEUTICALFORM

Concentratefororalsolutionforuseindrinkingwater.

Clearyellow-brownsolution.

4. CLINICALPARTICULARS

4.1 Targetspecies

Cattle(calves),sheep(lambs),swineandchickens

4.2 Indicationsforuse,specifyingthetargetspecies

Treatmentofgastrointestinalinfectionscausedbynon-invasiveEscherichiacoli

susceptibletocolistin.

4.3 Contraindications

Donotuseincaseofhypersensitivitytopolypeptideantibioticsortoanyofthe

excipients.

Donotuseincaseofresistancetothepolymyxin.

4.4 Specialwarningsforeachtargetspecies

Useoftheproductshouldbebasedonsusceptibilitytestingandtakeinto

accountofficialandlocalantimicrobialspolicies.

Revised:December2010

AN:00921/2010

Page2of6

4.5 Specialprecautionsforuse

i.Specialprecautionsforuseinanimals

Usingtheveterinarymedicinalproduct(antimicrobials)inpoultryshouldbein

accordancewithCommissionRegulationEC1177/2006andsubsequent

nationalrequirements.

Inthecaseofnewbornanimalsandofanimalswithseveregastrointestinaland

renaldisorderstheabsorptionofcolistinmaybeincreased.Neuro-and

nephrotoxicalterationsmayoccur.

ii.Specialprecautionstobetakenbythepersonadministeringtheveterinary

medicinalproducttoanimals

Peoplewithknownhypersensitivitytopolymyxinsshouldavoidcontactwiththe

veterinarymedicinalproduct.

Itisrecommendedtoweargloveswhenhandlingoradministeringthe

product.

Donoteat,drinkorsmokewhilehandlingtheproduct.

Incaseofaccidentaleyeexposure,washwithplentyofwaterandseekmedical

adviceimmediatelyandshowthelabeltothephysician.

Washhandsafteruse.

4.6Adversereactions(frequencyandseriousness)

Noneknown.

4.7Useduringpregnancy,lactationorlay

Thesafetyoftheveterinarymedicinalproducthasnotbeenestablishedduring

pregnancy,lactationorlayinthetargetspecies.Useonlyaccordinglytothe

risk/benefitoftheveterinarian.

Usingtheveterinarymedicinalproduct(antimicrobials)inpoultryshouldbein

accordancewithCommissionRegulationEC1177/2006andsubsequent

nationalrequirements.

4.8Interactionwithothermedicinalproductsandotherformsofinteraction

Afteroraladministrationofcolistinsulphateinteractionwithanaestheticsand

myorelaxantsmaynotbeexcludedinindividualcases.Thecombinationwith

aminoglycosidesandlevamisoleshouldbeavoided.Theeffectsofcolistin

sulphatemaybeantagonizedbybinarycations(iron,calcium,magnesium)and

byunsaturatedfattyacidsandpolyphosphates.

4.9 Amountstobeadministeredandadministrationroute

Dosage:

Tobeadministeredorally:

Forcalves,lambsandpigstherecommendeddoseis100000IUofcolistinper

kilogrambodyweightdailyfor3-5consecutivedays.Therecommendeddaily

Revised:December2010

AN:00921/2010

Page3of6

doseshouldbedividedintotwoiftheproductistobeadministereddirectlyinto

themouthoftheanimal.

Forpoultrytherecommendeddoseis75000IUofcolistinperkilogrambody

weightdailyfor3-5consecutivedays.

Administrationviadrinkingwater

Theuptakeofmedicatedwaterdependsonthephysiologicalandclinical

conditionsoftheanimals.Inordertoobtainthecorrectdosage,theconcentration

ofcolistinhastobeadjustedaccordingly.Carefullycalculatethetotalbodymass

tobetreatedandthetotaldailywaterconsumptionbeforeeachtreatment.

Medicatedwatershouldbemadeeveryday,immediatelypriortoprovision

Themedicatedwatershouldbetheonlysourceofdrinkingwaterfortheanimals

fortheentiredurationofthetreatmentperiod.

Withthefollowingformulawecancalculateanexactdosage:

.....mlColiplus

perkgbody

weightandday

x Average

body

weight(kg)

=....mlColiplus

perlitreof

drinkingwater

Averagedailywaterintake(l/animal)

Administrationwithoutadosingpump:

Thetreatmentisdistributedinatankoveraperiodof24hours,for3consecutive

days.

Coliplusisaddedtoavolumeofthedrinkingwatercorrespondingtothevolume

consumedbytheanimalsoverthetreatmentperiod(24hours)toachieveadose

ofIUofcolistinperkgbodyweight.Thefollowingsequentialstepsshouldbe

followed:

Fromthedosageregimenandthetotalweightofanimalstobetreated,

determinethenecessaryquantityofactiveingredient,anddeducethenecessary

quantityofcommercialproduct.

Determinethemeanwaterconsumptionoftheanimalstobetreatedover24

hours.

Thefollowingformulacanbeapplied:

1) Calculationofproductsolutionvolumeateachday(V):

V(ml)=(DosageperdayinIU/kgb.w.xTotalweightofanimalstotreat)/

2,000,000IU.

2) Calculationofthequantityofdrinkingwatertoprepare(Q

water ):

water (L):(Meanindividualwaterconsumption/day)x(Numberofanimalstobe

treated)

Administrationviaadosingpump

Thetreatmentisdistributedoveraperiodof24hours,for3consecutivedays.

Revised:December2010

AN:00921/2010

Page4of6

Adosingpumpisusedtoaddastocksolutionatapre-determinedconcentration

tothedrinkingwater.Thepumpedvolumeisconstant,butthedrinkingfrequency

dependsontheflowrateofthecircuit.Theflowrate(F)throughthepumpisa

percentage.

Iftheproductisadministeredwithanautomateddrinkingwatersystem,wehave

tocalculatethevolumeandtheconcentrationofthestocksolution.Thefollowing

sequentialstepsshouldbefollowed:

1)Calculationofproductsolutionvolumeateachdistribution(V):

V(ml)=(DosageperdayinIU/kgb.w.xTotalweightofanimalstotreat)/

2,000,000IU

2)Calculationofthedrinkingwaterconcentration(C):

C(ml/L)=V/Totalvolumeofwaterconsumedbytheanimalsin24hours.

3)Calculationofthestocksolutionvolume(V

stock )

stock (L)=Totalvolumeofwaterconsumedbytheanimalsin24hoursxF

4)Calculationofthestocksolutionconcentration(Cstock):

stock (ml/L)=C/F”

4.10Overdose(symptoms,emergencyprocedures,antidotes),ifnecessary

None.

4.11Withdrawalperiod(s)

Meatandoffal:Calves,Lambs,PigandPoultry:1day

Eggs:Zerodays

Notpermittedforuseinanimalsproducingmilkforhumanconsumption.

5. PHARMACOLOGICALPROPERTIES

Pharmacotherapeuticgroup:intestinalanti-infectives,antibiotics.

ATCvetcode:QA07AA10

Revised:December2010

AN:00921/2010

Page5of6

5.1 Pharmacodynamicproperties

Colistinisapolypeptideantibioticbelongingtothepolymyxinclass.

Colistinexertsabactericidalactiononsusceptiblebacteriastrainsbydisruption

ofthebacteriacytoplasmicmembraneleadingtoanalterationofcellpermeability

andthenaleakageofintracellularmaterials.Colistinisbactericidalandis

primarilyeffectiveagainstarangeofgramnegativebacteria,suchas

enterobacteriaceaeandinparticularEscherichiacoli.Colistinpossesses

virtuallynoactivityagainstgram-positivebacteriaandfungi.

Gram-positivebacteriaarenaturallyresistanttocolistin,asaresomespeciesof

gram-negativebacteriasuchasProteusandSerrati.However,acquired

resistanceofgram-negativeentericbacteriatocolistinisrareandexplainedbya

singlestepmutation.

InvitrosensibilityofColistinagainstEscherichiacoliandSalmonella

typhimuriumstrainsisolatedfrompigsandEscherichiacoli,Salmonella

enteritidisandSalmonellatyphimuriumstrainsisolatedfrompoultryhavebeen

determined,withthefollowingMIC

50 andMIC

values:

50 MIC

90

Escherichiacolifrompigs 0,19µg/ml 4,0µg/ml

Salmonellatyphimuriumfrompigs 3,0µg/ml 4,0µg/ml

Escherichiacolifrompoultry 0,25µg/ml 0,38µg/ml

Salmonellatyphimuriumfrompoultry 3,0µg/ml 4,20µg/ml

Salmonellaenteritidisfrompoultry 3,0µg/ml 4,20µg/ml

AccordingtotheNCCLSstandard,thecriticalconcentrationforresistanceof

colistinis16µg/ml.ThesensitivityofEscherichiacoliandSalmonellaspeciesin

cattleandsheepissimilartothesensitivityofpigsandpoultrypathogens.These

valueswereobtainedin2006.

5.2 Pharmacokineticparticulars

Colistinispoorlyabsorbedfromthegastro-intestinaltract.Incontrasttoverylow

concentrationofcolistininserumandtissues,highandpersistentamountsare

presentwithinthedifferentsectionsofthegastro-intestinaltract.

Nosignificantmetabolismisobserved.

Colistinisalmostexclusivelyeliminatedviathefaeces.

6. PHARMACEUTICALPARTICULARS

6.1Listofexcipients

Benzylalcohol

EDTAdisodiumsalt

Purifiedwater

6.2 Incompatibilities

Noneknown.

Revised:December2010

AN:00921/2010

Page6of6

6.3 Shelflife

Shelf-lifeoftheveterinarymedicinalproductaspackagedforsale:2years

Shelf-lifeafterfirstopeningtheimmediatepackaging:60days

Shelf-lifeafterdilutionorreconstitutionaccordingtodirections:24hoursafter

dilutioninwater.

6.4.Specialprecautionsforstorage

Storebelow25°C

6.5Natureandcompositionofimmediatepackaging

Natureofcontainer:

WhiteHDPEcontainerwithtamper-evidentaluminiumsealandHDPEscrew

cap

Packagesizes:250ml,1litreand5litres.

Notallpacksizesmaybemarketed.

6.6 Specialprecautionsforthedisposalofunusedveterinarymedicinal

productorwastematerialsderivedfromtheuseofsuchproducts

Anyunusedveterinarymedicinalproductorwastematerialsderivedfrom

suchveterinarymedicinalproductsshouldbedisposedofinaccordancewith

localrequirements.

7. MARKETINGAUTHORISATIONHOLDER

DIVASA-FARMAVIC,S.A.

Ctra.SantHipòlit,km71

08503GURB-VIC

Barcelona(Spain)

Tel:+34938860100

Fax:+34938860131

8. MARKETINGAUTHORISATIONNUMBER

Vm33229/4000

9. DATEOFFIRSTAUTHORISATION

8December2010

10. DATEOFREVISIONOFTHETEXT

December2010

25-10-2018

Safety of zinc chelate of methionine sulfate for the target species

Safety of zinc chelate of methionine sulfate for the target species

Published on: Wed, 24 Oct 2018 00:00:00 +0200 Zinc chelate of methionine sulfate is intended to be used as a nutritional additive (functional group: compounds of trace elements). The additive is zinc chelated with methionine in a molar ratio 1:1. It is intended to supply zinc as a nutritional additive to all animal species/categories. In 2017, the EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) adopted an opinion on the safety and efficacy of zinc chelate of methionine su...

Europe - EFSA - European Food Safety Authority Publications

2-7-2018

Fagron Sterile Services Issues Voluntary Nationwide Recall of Neostigmine Methylsulfate 1mg/mL, 5mg per 5mL and Neostigmine Methylsulfate 1mg/mL, 3mg per 3mL, in a 5mL syringe Due to Mislabeling

Fagron Sterile Services Issues Voluntary Nationwide Recall of Neostigmine Methylsulfate 1mg/mL, 5mg per 5mL and Neostigmine Methylsulfate 1mg/mL, 3mg per 3mL, in a 5mL syringe Due to Mislabeling

Fagron Sterile Services is voluntarily recalling two (2) lots of Neostigmine Methylsulfate 5mL syringes to the user/hospital/clinic level. The specified product lots are being recalled because of a confirmed customer complaint that some syringe units containing Neostigmine Methylsulfate 1mg/mL, 5mg per 5mL are incorrectly labelled as Neostigmine Methylsulfate 1mg/mL, 3mg per 3mL. Secondary packages are properly labelled as Neostigmine Methylsulfate 1mg/mL, 5mg per 5mL.

FDA - U.S. Food and Drug Administration

30-10-2018

EU/3/18/2072 (FGK Representative Service GmbH)

EU/3/18/2072 (FGK Representative Service GmbH)

EU/3/18/2072 (Active substance: 6'-(R)-methyl-5-O-(5-amino-5,6-dideoxy-alpha-L-talofuranosyl)-paromamine sulfate) - Orphan designation - Commission Decision (2018)7273 of Tue, 30 Oct 2018 European Medicines Agency (EMA) procedure number: EMA/OD/102/18

Europe -DG Health and Food Safety

27-6-2018

EU/3/15/1606 (Bayer AG)

EU/3/15/1606 (Bayer AG)

EU/3/15/1606 (Active substance: (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate) - Transfer of orphan designation - Commission Decision (2018)4094 of Wed, 27 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/184/15/T/02

Europe -DG Health and Food Safety

14-5-2018

Girolan and its associated name Apralan

Girolan and its associated name Apralan

Girolan and its associated name Apralan (Active substance: Apramycin sulfate) - Community Referrals - Art 34 - Commission Decision (2018)2989 of Mon, 14 May 2018 European Medicines Agency (EMA) procedure number: EMEA/V/A/122

Europe -DG Health and Food Safety

21-3-2018

EU/3/16/1714 (IQVIA RDS Ireland Limited)

EU/3/16/1714 (IQVIA RDS Ireland Limited)

EU/3/16/1714 (Active substance: 6'-(R)-methyl-5-O-(5-amino-5,6-dideoxy-a-L-talofuranosyl)-paromamine sulfate) - Transfer of orphan designation - Commission Decision (2018)1823 of Wed, 21 Mar 2018 European Medicines Agency (EMA) procedure number: EMA/OD/119/16/T/01

Europe -DG Health and Food Safety